Infectivity of amyloid diseases
Abstract
To date, transmissibility of amyloid diseases has not been thoroughly investigated. Although only some of these conformational disorders are considered infectious, all amyloid diseases could be infectious under certain conditions. For transmissibility, endogenous expression of an amyloidogenic peptide required, as well as the presence of an inoculum that is rich in amyloid fibrils and/or their precursors. Notably, administration of one type of amyloid might result in deposition of a different amyloid. Various cofactors could be essential for transmission - some might chaperone the amyloid peptides and/or fibrils, thereby directly facilitating their propagation; others might indirectly stabilize and/or increase levels of conformers with a high beta-sheet content. It is possible that these chaperones are induced by inflammation, which itself can lead to secondary amyloidosis. Thus, amyloid-related therapeutic approaches should not be based on administration of amyloidogenic peptides in conjunction with an inflammatory stimulus, such as in a recently halted clinical trial for Alzheimer's disease.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
This type of spreading mechanism is thought to govern disease propagation in all amyloid diseases and related proteinopathies.
“This type of spreading mechanism is thought to govern disease propagation in all amyloid diseases and related proteinopathies235.”
From Tau-targeting therapies for Alzheimer disease (2018) · cites this paper as [235]
Cites
Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse
Schenk, D., Barbour, R., Dunn, W., Gordon, G., Grajeda, H., Guido, T., Hu, K., Huang, J., Johnson-Wood, K., Khan, K., et al. (1999) · Nature · doi:10.1038/22124 · Cited by 3,160 · see citing works
Telling, G. C., Scott, M., Mastrianni, J. A., Gabizon, R., Torchia, M., Cohen, F. E., DeArmond, S. J., & Prusiner, S. B. (1995) · Cell · doi:10.1016/0092-8674(95)90236-8 · Cited by 854 · see citing works
Experimental Transmission of a Kuru-like Syndrome to Chimpanzees
Gajdusek, D. C., Gibbs, C. J., & Alpers, M. P. (1966) · Nature · doi:10.1038/209794a0 · Cited by 837 · see citing works
Brown, P., Gibbs, C. J., Rodgers‐Johnson, P., Asher, D. M., Sulima, M. P., Bacote, A. E., Goldfarb, L. G., & Gajdusek, D. C. (1994) · Annals of Neurology · doi:10.1002/ana.410350504 · Cited by 813 · see citing works
Neurodegenerative Diseases and Prions
Prusiner, S. B. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105173442006 · Cited by 767 · see citing works
Breathnach, S. M. (1988) · Journal of the American Academy of Dermatology · doi:10.1016/s0190-9622(88)70001-8 · Cited by 621 · see citing works
Kane, M. D., Lipinski, W. J., Callahan, M. J., Bian, F., Durham, R. A., Schwarz, R. D., Roher, A. E., & Walker, L. C. (2000) · The Journal of Neuroscience · doi:10.1523/jneurosci.20-10-03606.2000 · Cited by 394 · see citing works
Transmissibility of systemic amyloidosis by a prion-like mechanism
Lundmark, K., Westermark, G. T., Nyström, S. N., Murphy, C. L., Solomon, A., & Westermark, P. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.092205999 · Cited by 278 · see citing works
Sigurdsson, E. M., Scholtzova, H., Mehta, P. D., Frangione, B., & Wısnıewskı, T. (2001) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)61715-4 · Cited by 258 · see citing works
Self-citationPathology, diagnosis and pathogenesis of AA amyloidosis
Röcken, C., & Shakespeare, A. (2002) · Virchows Archiv · doi:10.1007/s00428-001-0582-9 · Cited by 213 · see citing works
Induction of β(A4)-amyloid in primates by injection of Alzheimer’s disease brain homogenate
Baker, H. F., Ridley, R. M., Duchen, L. W., Crow, T. J., & Bruton, C. J. (1994) · Molecular Neurobiology · doi:10.1007/bf02778005 · Cited by 149 · see citing works
Acceleration of amyloid protein A amyloidosis by amyloid-like synthetic fibrils
Johan, K., Westermark, G. T., Engström, U., Gustavsson, Å., Hultman, P. A., & Westermark, P. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.5.2558 · Cited by 147 · see citing works
A synthetic peptide initiates Gerstmann-Sträussler-Scheinker (GSS) disease in transgenic mice
Kaneko, K., Ball, H. L., Wille, H., Zhang, H., Groth, D., Torchia, M., Tremblay, P. J., Safar, J., Prusiner, S. B., DeArmond, S. J., et al. (2000) · Journal of Molecular Biology · doi:10.1006/jmbi.1999.3386 · Cited by 133 · see citing works
Qiao, X., Cummins, D. J., & Paul, S. M. (2001) · European Journal of Neuroscience · doi:10.1046/j.0953-816x.2001.01666.x · Cited by 119 · see citing works
Conformational mimicry in Alzheimer's disease. Role of apolipoproteins in amyloidogenesis.
Wısnıewskı, T., Golabek, A. A., Kida, E., Wisniewski, K. E., & Frangione, B. (1995) · Europe PMC (PubMed Central) · Cited by 107 · see citing works
Self-citationTransmission of Mouse Senile Amyloidosis
Xing, Y., Nakamura, A., Chiba, T., Kogishi, K., Matsushita, T., Li, F., Guo, Z., Hosokawa, M., Mori, M., & Higuchi, K. (2001) · Laboratory Investigation · doi:10.1038/labinvest.3780257 · Cited by 106 · see citing works
A “Protease Activation Cascade” in the Pathogenesis of Alzheimer's Disease
Nixon, R. A. (2000) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2000.tb05570.x · Cited by 102 · see citing works
The immunobiology of TSE diseases
Mabbott, N. A., & Bruce, M. E. (2001) · Journal of General Virology · doi:10.1099/0022-1317-82-10-2307 · Cited by 85 · see citing works
Sigurdsson, E. M., Lee, J. M., Dong, X.-W., Hejna, M. J., & Lorens, S. A. (1997) · Neurobiology of Aging · doi:10.1016/s0197-4580(97)00154-1 · Cited by 79 · see citing works
Self-citationPrion Diseases and the Immune System
Aucouturier, P., Carp, R. I., Carnaud, C., et al. (2000) · Clinical Immunology · doi:10.1006/clim.2000.4875 · Cited by 73 · see citing works
Cohen, A. S., & La, J. (1992) · PubMed · Cited by 60 · see citing works
Prions and the lymphoreticular system
Weissmann, C., Raeber, A. J., Montrasio, F., Hegyi, I., Frigg, R., Klein, M. A., & Aguzzi, A. (2001) · Philosophical Transactions of the Royal Society B Biological Sciences · doi:10.1098/rstb.2000.0763 · Cited by 57 · see citing works
New clothes for amyloid enhancing factor (AEF): Silk as AEF
Kisilevsky, R., Lernieux, L., Boudreau, L. R., et al. (1999) · Amyloid · doi:10.3109/13506129909007309 · Cited by 55 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Li, J.-Y., Englund, E., Holton, J. L., Soulet, D., Hagell, P., Lees, A. J., Lashley, T., Quinn, N. P., Rehncrona, S., Björklund, A., et al. (2008) · Nature Medicine · doi:10.1038/nm1746 · Cited by 1,845 · see citing works
Tau-targeting therapies for Alzheimer disease
Congdon, E. E., & Sigurdsson, E. M. (2018) · Nature Reviews Neurology · doi:10.1038/s41582-018-0013-z · Cited by 1,113 · see citing works
Self-citationBoutajangout, A., Ingadottir, J., Davies, P., & Sigurdsson, E. M. (2011) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2011.07337.x · Cited by 306 · see citing works
Self-citationTau immunotherapy for Alzheimer's disease
Pedersen, J. T., & Sigurdsson, E. M. (2015) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2015.03.003 · Cited by 247 · see citing works
Self-citationTau immunotherapies: Lessons learned, current status and future considerations
Sandusky-Beltran, L. A., & Sigurdsson, E. M. (2020) · Neuropharmacology · doi:10.1016/j.neuropharm.2020.108104 · Cited by 90 · see citing works
Self-citationSigurdsson, E. M. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-179937 · Cited by 76 · see citing works
Self-citation
- Authors
- Sigurdsson, E. M., Wisniewski, T., & Frangione, B.
- Affiliations
- New York University (US)
- Corresponding author
- Sigurdsson, Einar M
- ORCID
- Sigurdsson, Einar M
- Venue
- Trends in Molecular Medicine
- Publisher
- Elsevier BV
- Published
- 2002-09
- Volume
- 8
- Issue
- 9
- Pages
- 411-413
- ISSN
- 1471-4914 (ISSN-L)
- OpenAlex
- W2007898835
- Cited by
- 43
- References
- 23
- Citations by year
- 2024: 3 · 2020: 2 · 2019: 3 · 2018: 3 · 2016: 1 · 2015: 2 · 2013: 1 · 2012: 1
- FWCI
- 0.12
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Trends in Molecular Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Prion Diseases and Protein Misfolding
- Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Amyloidosis: Diagnosis, Treatment, Outcomes
- Keywords
- amyloidosis, transmissibility, amyloid fibrils, amyloidogenic peptides, AA amyloidosis, molecular chaperones, inflammation, β-sheet conformation, amyloid deposition, Alzheimer's disease
- MeSH terms
- Amyloid, Amyloidosis, Glycoproteins, Humans, Inflammation, Disease Transmission, Infectious, Molecular Chaperones
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
